The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor
Abstract
A truncated form of human glucose-dependent insulinotropic polypeptide (GIP), GIP(3–30)NH2, was recently identified as an antagonist of the human GIP receptor. This study examined the ability of GIP(3–30)NH2 to antagonize the physiological actions of GIP in glucose metabolism, subcutaneous abdominal adipose tissue blood flow (ATBF), and lipid metabolism in humans. Eight lean subjects were studied by measuring arteriovenous concentrations of metabolites and ATBF on three different occasions during hyperglycemic-hyperinsulinemic clamps with concomitant infusions of GIP, GIP(3–30)NH2, or both GIP and GIP(3–30)NH2. During infusion of GIP(3–30)NH2 alone and in combination with GIP, insulin levels and the total glucose amount infused to maintain the clamp were lower than during GIP alone. In addition, ATBF remained constant during the antagonist and increased only slightly in combination with GIP, whereas it increased fivefold during GIP alone. Adipose tissue triacylglyceride (TAG) and glucose uptake decreased, and the free fatty acid/glycerol ratio increased during the antagonist alone and in combination with GIP. The changes in glucose infusion rates and plasma insulin levels demonstrate an inhibitory effect of the antagonist on the incretin effect of GIP. In addition, the antagonist inhibited GIP-induced increase in ATBF and decreased the adipose tissue TAG uptake, indicating that GIP also plays a crucial role in lipid metabolism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“Previous in vitro and animal studies have shown that GIP may play a role in obesity and have suggested that GIP receptor may represent a target for the prevention and treatment of obesity (29,30).”
Self-citationAdipose tissue as a buffer for daily lipid flux
Frayn, K. (2002) · Diabetologia · doi:10.1007/s00125-002-0873-y · Cited by 752
Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314
Self-citationFrayn, K. N., Shadid, S., Hamlani, R., Humphreys, S. M., Clark, M. L., Fielding, B. A., Boland, O., & Coppack, S. W. (1994) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1994.266.3.e308 · Cited by 188
Incretin Hormone and Insulin Responses to Oral Versus Intravenous Lipid Administration in Humans
Lindgren, O., Carr, R. D., Deacon, C. F., Holst, J. J., Pacini, G., Mari, A., & Ahrén, B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0266 · Cited by 188
Self-citationAsmar, M., Simonsen, L., Madsbad, S., Stallknecht, B., Holst, J. J., & Bülow, J. (2010) · Diabetes · doi:10.2337/db10-0098 · Cited by 184 · cited 4×
“We have previously demonstrated that GIP infusions in the presence of elevated insulin concentrations increased ATBF and stimulated triacylglyceride (TAG) deposition in adipose tissue in lean humans (1), suggesting that GIP together with insulin are controllers of postprandial fat deposition.”
BackgroundMethodResultInfluentialSelf-citationRegulation of human subcutaneous adipose tissue blood flow
Frayn, K. N., & Karpe, F. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.200 · Cited by 172
Summers, L. K. M., Samra, J. S., Humphreys, S. M., Morris, R. J., & Frayn, K. N. (1996) · Clinical Science · doi:10.1042/cs0910679 · Cited by 167
Tseng, C., Kieffer, T. J., Jarboe, L. A., Usdin, T. B., & Wolfe, M. M. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119060 · Cited by 148
Sparre‐Ulrich, A. H., Hansen, L. S., Svendsen, B., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13323 · Cited by 112
Self-citation
Cited by
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Zhang, Q., Delessa, C. T., Augustin, R., Bakhti, M., Colldén, G., Drucker, D. J., Feuchtinger, A., Caceres, C. G., Grandl, G., Harger, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.015 · Cited by 322
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Metadata
- Authors
- Asmar, M., Asmar, A., Simonsen, L., Gasbjerg, L. S., Sparre-Ulrich, A. H., Rosenkilde, M. M., Hartmann, B., Dela, F., Holst, J. J., & Bülow, J.
- Affiliations
- Bispebjerg Hospital (DK)
- University of Copenhagen (DK)
- Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
- Corresponding author
- Asmar, Meena
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2017-06-30
- Volume
- 66
- Issue
- 9
- Pages
- 2363-2371
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2728467537
- Cited by
- 132
- References
- 32
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 14 · 2023: 8 · 2022: 16 · 2021: 14 · 2020: 14 · 2019: 22 · 2018: 10 · 2017: 2
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- European Foundation for the Study of Diabetes
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor antagonist, incretin effect, adipose tissue blood flow, adipose tissue glucose uptake, lipid metabolism, glucose metabolism, insulin secretion
- MeSH terms
- Adipose Tissue, Adult, Blood Glucose, Fatty Acids, Nonesterified, Gastric Inhibitory Polypeptide, Glucose, Glycerol, Humans, Male, Peptide Fragments, Receptors, Gastrointestinal Hormone, Triglycerides, Glucose Clamp Technique, Cross-Over Studies, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor. https://app.cochat.ai/papers/10.2337/db17-0480
- The paper
- Asmar, M., Asmar, A., Simonsen, L., Gasbjerg, L. S., Sparre-Ulrich, A. H., Rosenkilde, M. M., Hartmann, B., Dela, F., Holst, J. J., & Bülow, J. (2017). The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor. Diabetes. https://doi.org/10.2337/db17-0480
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.